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Abstract
Background: Carcinogenesis typically involves multiple somatic mutations in caretaker (DNA
repair) and gatekeeper (tumor suppressors and oncogenes) genes. Analysis of mutation spectra of
the tumor suppressor that is most commonly mutated in human cancers, p53, unexpectedly
suggested that somatic evolution of the p53 gene during tumorigenesis is dominated by positive
selection for gain of function. This conclusion is supported by accumulating experimental evidence
of evolution of new functions of p53 in tumors. These findings prompted a genome-wide analysis
of possible positive selection during tumor evolution.
Methods: A comprehensive analysis of probable somatic mutations in the sequences of Expressed
Sequence Tags (ESTs) from malignant tumors and normal tissues was performed in order to access
the prevalence of positive selection in cancer evolution. For each EST, the numbers of synonymous
and non-synonymous substitutions were calculated. In order to identify genes with a signature of
positive selection in cancers, these numbers were compared to: i) expected numbers and ii) the
numbers for the respective genes in the ESTs from normal  tissues.
Results: We identified 112 genes with a signature of positive selection in cancers, i.e., a significantly
elevated ratio of non-synonymous to synonymous substitutions, in tumors as compared to 37 such
genes in an approximately equal-sized EST collection from normal tissues. A substantial fraction of
the tumor-specific positive-selection candidates have experimentally demonstrated or strongly
predicted links to cancer.
Conclusion: The results of EST analysis should be interpreted with extreme caution given the
noise introduced by sequencing errors and undetected polymorphisms. Furthermore, an inherent
limitation of EST analysis is that multiple mutations amenable to statistical analysis can be detected
only in relatively highly expressed genes. Nevertheless, the present results suggest that positive
selection might affect a substantial number of genes during tumorigenic somatic evolution.
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Background
It is well established that most cancers are triggered by
somatic or, less commonly, germline mutations in care-
taker and gatekeeper genes [1-6]. The caretakers are
broadly defined DNA repair genes that are responsible for
maintenance of genome stability. Mutations in the care-
taker genes, which are considered to be typical tumor sup-
pressors, compromise genome stability and, more
specifically, increase the probability of mutation in the
gatekeepers which include both tumor suppressor genes
and oncogenes [3,7]. Tumor suppressors are genes that
control cell proliferation, in particular, by causing cell
death in response to DNA damage; accordingly, muta-
tional inactivation of tumor suppressors may cause trans-
formation. In contrast, oncogenes are genes that, when
mutated, acquire new functions promoting cell prolifera-
tion and, eventually, transformation [4].
Since the pioneering work of Theodore Boveri in the
beginning of the 20th century[8], tumorigenesis often has
been viewed as a somatic version of Darwinian evolution
[9-12]. This perspective implies positive selection of
mutations that are beneficial from the standpoint of an
individual cell, i.e., mutations that promote cell prolifera-
tion such as those activating the tumorigenic potential of
oncogenes and those inactivating tumor suppressors. In
the context of modern evolutionary synthesis, it is equally
obvious that tumor evolution should involve substantial
purifying selection against mutations impairing prolifera-
tion. Although the Darwinian view of tumorigenesis
seems to be increasingly gaining foothold, the interplay of
selective forces acting on mutations in specific genes is not
understood in detail.
Altogether, mutations in more than 200 human genes
have been implicated in cancer [13]. Currently, inactiva-
tion of tumor suppressors is considered to be the main
driving force of tumorigenesis. The most prominent and
best studied tumor suppressor is p53, a multifunctional
transactivator of transcription and regulator of cell prolif-
eration, programmed cell death, and repair [14-16]. The
p53 gene is mutated in nearly 60% of human tumors.
Many independent studies have shown that, in addition
to its tumor suppressor properties, p53 may also behave
as an oncogene[17]. Specifically, gain of new biochemical
(e.g., transactivation of transcription of genes that are not
affected by wild-type p53) and biological (e.g,, stimula-
tion of cell proliferation) functions resulting from p53
mutations has been demonstrated [18-22]. Compelling
evidence of p53 gain-of-function during tumorigenesis
has been provided by recent reports on mouse models of
Li-Fraumeni syndrome (LFS), a familial cancer predispo-
sition syndrome caused by germline p53 mutations. These
studies revealed substantial changes in the tumor spectra
of mice carrying common p53 mutations, indicating that
gain-of-function by p53 is important for tumorigene-
sis[23,24].
The conclusion that gain-of-function in p53 mutants is
important for tumorigenesis is strongly supported by the
results of bioinformatic analysis of the mutation spectra
of the p53 gene [25,26]. These studies yielded three lines
of evidence compatible with biologically relevant gain-of-
function in p53 mutants in tumors:
i) somatic mutations of p53 detected in various cancers
showed a highly significant excess of non-synonymous
over synonymous substitutions, which is the signature of
positive selection[27], ii) amino acid replacements caused
by cancer-associated mutations clustered within evolu-
tionarily conserved, functionally important regions of
p53, and iii) mutational hotspots, the sites of frequent
mutation which are subject to particularly strong positive
selection, differed depending on the type of tumor, which
suggests acquisition of distinct new functions by p53 in
different tumors.
These observations prompted us to ask whether positive
selection could also be detected in somatic mutants of
other cancer-related genes in tumors. Genes evolving
under positive selection during cancer progression could
be viewed as candidate new oncogenes. To delineate the
repertoire of such genes, we performed a genome-wide
search for positive selection during cancer evolution by
comparing the sequences of Expressed Sequence Tags
(EST[28]) from tumors to the corresponding genomic
sequences. The rationale of this analysis is to detect
somatic mutations in ESTs and identify genes that show a
significant excess of non-synonymous over synonymous
substitutions in tumors. In principle, EST libraries provide
ample material for analyzing somatic mutations in
tumors and normal tissues. The problem with this
approach is that differences between EST sequences and
the sequences of the respective reference genes from the
human genome may be caused by a variety of reasons
other than somatic mutation including sequencing errors,
incorrect assignment of an EST to a reference gene, and
single-nucleotide polymorphisms (SNPs).
Several recent, large scale studies employed EST collec-
tions for detecting cancer-associated SNPs and cancer-spe-
cific alternative splice forms. In particular, Xu and Lee
identified 316 human splice variant forms with a statisti-
cally significant cancer association; the structures of the
most abundant of these were supported by sequences of
the corresponding mRNAs isolated from tumors [29].
Another, larger-scale study by Gupta et al. reported 1120
tumor-specific splice isoforms with a high rate of valida-
tion by mRNA sequencing. However, when mRNA analy-
sis was performed, the tissue specificity of many of theseBMC Cancer 2006, 6:36 http://www.biomedcentral.com/1471-2407/6/36
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transcripts, particularly, those of low abundance, could
not be confirmed[30]. A study by Brentani et al. took a dif-
ferent approach by using ESTs to identify SNPs in a prede-
fined set of cancer-related genes; this resulted in the
identification of 237 previously known and 505 new
SNPs in these genes[31]. A comprehensive analysis by Qiu
and coworkers involved cross-mapping of the EST data-
base (dbEST) and the database SNP (dbSNP), yielding a
statistically significant association with tumors for 4865
SNPs[32].
These studies emphasize the potential of EST analysis for
detecting genomic and expression features associated with
cancer. However, they are not particularly informative in
terms of uncovering potential causative roles of individual
genes in tumorigenesis. We were interested in mining
dbEST for somatic mutations that could be positively
selected in cancers, which would make the respective
genes candidate oncogenes. The inherent problem of such
analysis is distinguishing somatic mutations from
sequencing errors and SNPs. However, the latter two
sources of sequence variation are not expected to produce
a signature of positive selection. Indeed, whatever biases
are prevalent among sequencing errors, they would not
effect the non-synonymous to synonymous substitutions.
The issue with SNPs, obviously, is more complex. How-
ever, most if not all human SNPs appear to be either selec-
tively neutral or slightly deleterious and do not show signs
of frequent positive selection[33,34]. Accordingly, the sig-
nature of positive selection, namely, an elevated non-syn-
onymous/synonymous substitution ratio [27,35], is
expected to be detectable among somatic mutations even
in the presence of some contamination by sequencing
errors and SNPs.
With this premise, we partitioned the EST sequence librar-
ies available through the dbEST database (NCBI, NIH,
Bethesda) into those originating from tumors (hereinafter
cancer ESTs) and those from normal tissues (normal
ESTs), and identified genes with a significant excess of
non-synonymous substitutions in each of the two sets.
The results suggest that positive selection is more pro-
nounced in somatic evolution of tumors than it is in nor-
mal tissues. Many genes with a signature of positive
selection in tumors have established or strongly predicted
links to cancer.
Results
Signatures of purifying and positive selection in cancer ests
The ESTs from both tumors and normal cells showed a
much lower ratio of non-synonymous to synonymous
substitutions than expected under the model of neutral
evolution (Table 1), indicating that most of these substi-
tution were genuine mutations subject to purifying selec-
tion rather than sequencing errors or neutral SNPs. This
notion was reinforced by the substantial, highly signifi-
cant deficit of nonsense mutations in both EST collections
compared to the neutral expectation (Table 1). Remarka-
bly, however, the excess of synonymous over non-synon-
ymous substitutions was less pronounced in cancer ESTs
than in normal ESTs. In other words, cancer ESTs showed
a significantly greater non-synonymous/synonymous
substitution ratio than the normal ESTs (Table 1). (P = 3.7
× 10-32 by Fisher's two-tail exact test) This observation sug-
gests that, compared to the somatic evolution of normal
cells, somatic evolution of cancers is characterized by
relaxed purifying selection and/or substantial positive
selection in some genes. The latter possibility was of spe-
cial interest because positive selection of somatic muta-
tions in cancers might imply that the change in function
of the respective genes was relevant for tumorigenesis and
could lead to prediction of previously undetected onco-
genes. Therefore we systematically screened cancer and
normal EST sequences for indications of positive selection
by counting synonymous and non-synonymous substitu-
tions after controlling for sequence quality and subtract-
ing the known SNPs (see Materials and Methods for
details).
This screening identified 112 genes with a significant
excess of non-synonymous over synonymous substitu-
tions compared to the random expectation in tumors and
37 such genes among normal ESTs (Tables 2 and 3; see
Additional file 1 ). The difference between the fractions of
Table 1: Putative somatic mutations in cancer and normal ESTs.
EST 
source
Total 
number 
of 
substitu
tions 
(N)
Numbe
r of 
synony
mous 
substitu
tions 
(Ns)
Numbe
r of 
non-
synony
mous 
substitu
tions 
(Na)
Numbe
r of 
nonsens
e 
substitu
tions 
(Nns)
Ns/Na Nns/N Ns exp Na exp Nns 
exp
Ns/Na 
exp
Nns/N 
exp
p_value 
χ2 Ns/
Na 
observe
d vs 
expecte
d
p_value 
χ2 Nns/
N 
observe
d vs 
expecte
d
Normal 429070 131244 286416 11410 0.46 0.027 111827 301723 15521 0.37 0.036 <10-10 <10-10
Cancer 253254 74090 172551 6613 0.43 0.026 64719 179818 8717 0.36 0.034 <10-10 <10-10BMC Cancer 2006, 6:36 http://www.biomedcentral.com/1471-2407/6/36
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genes with a significant excess of non-synonymous substi-
tutions in cancer and normal ESTs was highly statistically
significant (P < 10-7 by the Fisher's exact test). Further-
more, a comparison of the mutation spectra in cancer-spe-
cific ESTs in the 112 concatenated genes with the
mutation spectra of the same genes in ESTs from normal
tissues revealed highly significant differences (P < 10-
5)[36]. Many of the mutated ESTs contain so-called muta-
tional hotspots which, for the purpose of this study, were
operationally defined as sites with three or more muta-
tions (Tables 2 and 3; see Additional file 1 ). Specifically,
the 112 genes with excess of non-synonymous substitu-
tions in cancer ESTs contained 341 hotspots, whereas the
same genes contained 206 hotspots in ESTs from normal
tissues. Only 63 hotspots were represented in both sets of
ESTs, indicating the presence of a large number of cancer-
specific hotspots.
Excess of non-synonymous over synonymous substitu-
tions is considered to be a signature of positive selection
[27,35]. For 51 of the 112 genes with such a signature in
cancer ESTs, there was also a statistically significant excess
of non-synonymous substitutions in a direct comparison
with the normal ESTs derived from the same genes (Table
Distribution of non-synonymous substitutions in cancer and normal ESTs Figure 1
Distribution of non-synonymous substitutions in cancer and normal ESTs. from the protein tyrosine phosphatase IV A2 gene. 
The substitutions are shown in the form of amino acid replacements. Identical letters in the same position correspond to sub-
stitutions from different EST libraries. The alignments were constructed using the MACAW program [44]. Species name 
abbreviations: CANFA, Canis familiaris, GALGA, Gallus gallus, HOMSA, Homo sapiens, RATNO, Rattus norvegicus, XENTR, Xeno-
pus tropicalis. TETNI, Tetraodon nigrovirides.
                                                             V 
                                                             V 
Cancer                                   L                   V         T 
PTP_IVA2_HOMSA      MNRPAPVEISYENMRFLITHNPTNATLNKFTEELKKYGVTTLVRVCDATYDKAPVEK  
PTP_IVA2_CANFA      MNRPAPVEISYENMRFLITHNPTNATLNKFTEELKKYGVTTLVRVCDATYDKAPVEK  
PTP_IVA2_RATNO      MNRPAPVEISYENMRFLITHNPANATLNKFTEELKKYGVTTLVRVCDATYDKAPVEK  
PTP_IVA2_XENTR      MNRPAPVEISHECMRFLITHNPTNATLNKFTEELKKYGVTTLVRVCDATYDKAPVEK  
PTP_IVA1_GALGA   MARMNRPAPVEITYKNMRFLITHNPTNATLNKFIEELKKYGVTTVVRVCEATYDTAPVEK  
PTP_IVA1_XENTR   MARMNRPAPVEITYKNMRFLITHNPTNATLNKFIEELKKYGVTTLVRVCEATYDTALVEK  
PTP_IVA1_TETNI   MARMNRPAPVEITYKNMRFLITHNPTNATLSKFIEELKKYGVTTVVRVCEATYDATLVGK  
Normal                            C             M  G    F      P      Y 
                        G               G 
                        G               G                                  W 
Cancer                  G          *    G T I         F       VRS          W 
PTP_IVA2_HOMSA   EGIHVLDWPFDDGAPPPNQIVDDWLNLLKTKFREEPGCCVAVHCVAGLGRAPVLVALALI  
PTP_IVA2_CANFA   EGIHVLDWPFDDGAPPPNQIVDDWLNLLKTKFREEPGCCVAVHCVAGLGRAPVLVALALI  
PTP_IVA2_RATNO   EGIHVLDWPFDDGAPPPNQIVDDWLNLLKTKFREEPGCCVAVHCVAGLGRAPVLVALALI  
PTP_IVA2_XENTR   EGIQVLDWPFDDGAPPPTQIVDDWLNLLKTKFREEAGCCIAVHCVAGLGRAPVLVALALI  
PTP_IVA1_GALGA   EGIQVLDWPFDDGAPPSNQIVDDWLNLLKVKFREEPGCCIAVHCVAGLGRAPVLVALALI  
PTP_IVA1_XENTR   EGIQVLDWPFDDGAPPSNQIVDDWLNLLKMKFREEPGCCIAVHCVAGLGRAPVLVALALI  
PTP_IVA1_TETNI   EGIQVLDWPFDDGAPPSNQIVDDWLNLLKLKFREEPGCCVAVHCVAGLGRAPVLVALALI  
Normal                            I     G   *            S       R P     S 
Cancer                 H N    L   S V      W 
PTP_IVA2_HOMSA   ECGMKYEDAVQFIRQKRRGAFNSKQLLYLEKYRPKMRLRFRDTNGH---CCVQ         
PTP_IVA2_CANFA   ECGMKYEDAVQFIRQKRRGAFNSKQLLYLEKYRPKMRLRVRDTNGH---CCVQ         
PTP_IVA2_RATNO   ECGMKYEDAVQFIRQKRRGAFNSKQLLYLEKYRPKMRLRSRDTNGH---CCVQ         
PTP_IVA2_XENTR   ECGMKYEDAVQFIRQKRRGAFNSKQLLYLEKYRPKMRLRFKDPNNH---CCMQ         
PTP_IVA1_GALGA   ECGMKYEDAVQFIRQKRRGAFNSKQLLYLEKYRPKMRLRFKDSNGHRNNCCIQ         
PTP_IVA1_XENTR   ESGMKYEDAVQFIRQKRRGAFNSKQLLYLEKYRPKMRLRFKDSNGHRNNCCIQ         
PTP_IVA1_TETNI   ECGMKYEDAVQFIRQKRRGAFNSKQLFYLEKYRPKMRLRFKDSNGHRNNCCIQ         
Normal                   P      T             D   L        P BMC Cancer 2006, 6:36 http://www.biomedcentral.com/1471-2407/6/36
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Distribution of non-synonymous substitutions in cancer and normal ESTs Figure 2
Distribution of non-synonymous substitutions in cancer and normal ESTs. from the microsomal glutathione S transferase gene. 
The designations are as in Fig. 1. Additional species name abbreviations: ANOGA, Anopheles gambiae, DANRE, Danio rerio, 
DROME, Drosophila melanogaster, MUSMU, Mus musculus, STRPU, Strongylocentrotus purpuratus, XENLA, Xenopus laevis.
                             LLL                                   LL 
                              L                           L        L 
Cancer                   D    SV              A   C  W    LT       S QE  
GSTM_HOMSA   MVDLT--QVMDDEVFMAFASYATIILSKMMLMSTATAFYRLTRKVFANPEDCVAFGKGEN  
GSTM_MUSMU   MADLK--QLMDNEVLMAFTSYATIILAKMMFLSSATAFQRLTNKVFANPEDCAGFGKGEN  
GSTM_GALGA   MAKST--QLIDNEVFRAYATYAAIVLLKMMLMSLVTAYFRITRKAFANPEDTASFGKGDS  
GSTM_XENLA   MANLS--SLMDSEVLRAYATYSTIVLLKMMLMSIATAYFRLTKKVFANPEDARVHAKGGD  
GSTM_DANRE   MAEVV--HMIDSEVFLAFSTYATIVILKMMLMSLMTSYLRLTKQVFSNLEDTAMAIAEDK  
GSTM_STRPU   -------MSNSEEALKCFATYAGLVTLKMMMLGPLTGFYRTRDSAYANEEDFVLTGLKDR  
GSTM_ANOGA   MTTLL--QNVNEEVFRTYVFWTAVLVVKMLAMSVLTGRQRFRKKVFANPEDIQPSKKGAQ  
GSTM_DROME   MASPVELLSLSNPVFKSFTFWVGVLVIKMLLMSLLTAIQRFKTKTFANPEDLMSPKLKVK  
Normal               G        L C  P          RS   CD W   IL   *   TL   *H
                                                   C V   G        S    * 
                                                     W   V             E 
                                                            
                                           M                      
                                          M                      
                                S          M         E F GT     IC       N 
Cancer                   C G  Q H   D    VRNGI       E C DT  M  IS   W   A 
GSTM_HOMSA   AKKYLRTDDRVERVRRAHLNDLENIIPFLGIGLLYSLSGPDPSTAIL-HFRLFVGARIYHT 
GSTM_MUSMU   AKKFLRTDEKVERVRRAHLNDLENIVPFLGIGLLYSLSGPDLSTA-LIHFRIFVGARIYHT 
GSTM_GALGA   AKKFLRIDADVERVRRGHLNDLENIVPFFGIGLLYALCGPDLSTA-LLHFRIFAGARILHT 
GSTM_XENLA   TKKLLKTDEDVERVRRCHLNDIENIVPFVAIGLIYALTNPNLASA-LLHFRIFTGSRILHT 
GSTM_DANRE   KKLV-RTDPDVERVRRCHLNDLESIVPFVVIGLLYALTGPVLSTA-LLHFRVFVVSRFIHT 
GSTM_STRPU   RPVF--NHPMIERIRRCNLNDLENIVPFVIIGGLFAVYSGSSLSTILWHYRIFVASRFLHS 
GSTM_ANOGA   PKFD---DPDVERVRRAHRNDLENILPFFAIGLLYMLTNPEPFIAI-NLFRAVAIARIVHT 
GSTM_DROME   FDDP-----NVERVRRAHRNDLENILPFFAIGLLYVLTDPAAFLAI-NLFRAVGIARIVHT 
Normal            L     G E  P      H T    S   C  I  NLP     N KISAE W  Q 
                        K           I      M         E Y       K 
                        G                  M         E C 
                        G                  M         E S 
                        *                            E 
                                 
             M                L  
             M                LA  
             F                SF           W 
Cancer       LE  F T  KPS     YF      P  NKW 
GSTM_HOMSA   IAY-LTPLPQPNRALSFFVGYGVTLSMAYRLLKSKLYL                        
GSTM_MUSMU   IAY-LTPLPQPNRGLAFFVGYGVTLSMAYRLLRSRLYL                        
GSTM_GALGA   FAY-LIPLPQPSRGLSWAVGYAVTISMAYKVLSKALYL                        
GSTM_XENLA   IAY-LLPLPQPSRGLTWVVGYLVTISMAVGILRGVLYL                        
GSTM_DANRE   VAY-IMALPQPTRGVAFGVGLLTTLSMAYRVLTTALFL                        
GSTM_STRPU   IAY-LLPLPQPSRALCYFFGIGTNLSMAIRLLMNTWFL                        
GSTM_ANOGA   LVYAVVVIPQPARGLSWAIAYFATAYMAVKTALFFL--                        
GSTM_DROME   LVYAVVVVPQPSRALAFFVALGATVYMALQVIASAAF-                        
Normal       M   S  FSH KG     F     PFL  WV
                 S  FR   K 
                 W BMC Cancer 2006, 6:36 http://www.biomedcentral.com/1471-2407/6/36
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Distribution of non-synonymous substitutions in cancer and normal ESTs Figure 3
Distribution of non-synonymous substitutions in cancer and normal ESTs. from the claudin 7 gene. The designations are as in 
Fig. 1. The site with multiple valine substitutions corresponds to a SNP. Additional species name abbreviations: HALRO, Halo-
cynthia roretzi, TAKRU, Takifugu rubripes.
Cancer 
CLAUDIN7_HOMSA   MANSGLQLLGFSMALLGWVGLVACTAIPQWQMSSYAGDNIITAQAMYKGLWMDCVTQSTG   
CLAUDIN7_MUSMU   MANSGLQLLGFSMAMLGWVGLIASTAIPQWQMSSYAGDNIITAQAMYKGLWMECVTQSTG   
CLAUDIN_GALGA    MASGGLQLLGFVLAFLGWMGIIISTAMPQWKMASYAGDNIVTAQALYEGLWMSCAMQSTG   
CLAUDIN_XENLA    MANSGLQLLGFVLAMLGWIALIAATIMPQWKMSSYAGDQIITAVAIYQGLWMSCATQSTG   
CLAUDIN_TAKRU    MANSGLQILGFALALLGVIGLIIGTILPQWKMSAYVGDNIITAVAMYEGLWMSCAFQSTG   
CLAUDIN_DANRE    MANSGVQLLGFGLSLIGIIGLIVGTILPQWKMSAYVGDSIITAVATYQGLWMSCAFQSTG   
CLAUDIN_HALRO    MVNEVLQVFGFLLTVLGWLLSIVTCSISSWKRSDVKGEVIESITRTT-GLWIRCTQQATG   
Normal                                 V         T C                       
                                                                         
                                                           R                 
Cancer                                                     I         Q           
CLAUDIN7_HOMSA   MMSCKMYDSV-LALSAALQATRALMVVSLVLGFLAMFVATMGMKCTRCGGDDKVKKARIA  
CLAUDIN7_MUSMU   MMSCKMYDSV-LALPGALQATRALMVVSLVLGFLAMFVATMGMKCTRCGGDDKAKKARIA  
CLAUDIN_GALGA    QIQCKVYDSL-LKLEGSLQATRALMVAAILLGLVGVFVAVTGMKCMKCMEDDQVKKMRMA  
CLAUDIN_XENLA    QIQCKVYDSI-LQLDASLQATRALMVVSIILGIFGIAVSTMGMKCTTCGGDDKVKKSRIA  
CLAUDIN_TAKRU    QIQCKVYDSI-LQLNSALQATRALMIVSIILVVAGLGVSCMGMKCTTCGGDDKTRKSRIA   
CLAUDIN_DANRE    QLQCKIYDSI-LQLDSDLQATRALMIVGIIVSIAGLGVASIGMKCTTCGADDKVRKTRTA  
CLAUDIN_HALRO    HWTCDNYDSYFLGLPVPLQGARATTLLSLLLGFFGILLAIFGLSCTTIAAENARLKARMV  
Normal               N          PA      I                      L  A      G 
                           
                                                                         L 
Cancer              S      S   L  W            M          NH      C      CT   
CLAUDIN7_HOMSA   MGGGIIFIVAGLATLVAC------SWYGHQIVTDFYNPLIPTNI-KYEFGPAIFIGWAGS   
CLAUDIN7_MUSMU   MTGGIVFIVAGLAALVAC------SWIGHQIVTDFYNPLTPMNV-KYEFGPAIFIGWAGS   
CLAUDIN_GALGA    VFGGVIFIIAGLSALVAT------SWYGNRVARAFYDPFTPVNT-RFEFGSALFIGWAAA   
CLAUDIN_XENLA    MTGGFVFLLGGLAALIAC------SWYGNQIIRDFYNPLLPINT-KYEFGAGVFLGWAGS   
CLAUDIN_TAKRU    MTGGIVILIGGWIALTSLCAIVACSWYAHDIIQAFYNPFTPVNT-KYEFGSAIFIAWAGA   
CLAUDIN_DANRE    MTGGIILLVGALCAVVAC------SWFAHNVIRAFYNPFTPVNT-KFEFGAAIFIAWGGS   
CLAUDIN_HALRO    VASGMLHVAGGVSLGTGV------CWFAATVLQDYQNPGNQVSAGRYVYGEALFVGWAAM   
Normal                I      A                 M           T        P
                                       VVVVV 
                                       VVVVV                                    
                                        VVV 
Cancer                                   V 
CLAUDIN7_HOMSA   ALVILGGALLSCSCPGNESKAGYRAP------------RSYPKSNSSKEYV            
CLAUDIN7_MUSMU   ALVLLGGALLSCSCPGSESKAAYRAP------------RSYPKSNSSKEYV            
CLAUDIN_GALGA    SLALLGGAFLCCSCPRSETSYPPSRG------------YPKNAPSTGKDYV            
CLAUDIN_XENLA    FLVLIGGGLLSCSCSRKNNYQKGYPKSG----------AKSKVPSSGRDYV            
CLAUDIN_TAKRU    FLTVVGGGMLAASCPRGKSTPR----------------YPMSKPPSSKEYV            
CLAUDIN_DANRE    FLDVLGGAMLAASCPRSKQVSKYPKSN-----------STRSANGSNKEYV            
CLAUDIN_HALRO    VVGILGGIAMCISSWSTKDDDDHHHHHHMERHIPPYTYNPPRPKQNSTEYI            
Normal                                   V 
                                        VVV 
                                       VVVVV 
                                       VVVVV BMC Cancer 2006, 6:36 http://www.biomedcentral.com/1471-2407/6/36
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2; see Additional file 1 and Methods for details). Notably,
these genes did not seem to have an excess of nonsense
mutations (Table 2; see Additional file 1) which suggests
that they are not subject to strong selection for loss of
function and that at least some of the positively selected
amino acid replacements might be associated with gain-
of-function.
The methodology employed here dictates that the list of
genes with cancer-specific positive selection (CASPS) is
dominated by genes that are highly expressed, particu-
larly, in tumors; typically, statistical significance of the
positive selection signature could be demonstrated only
for genes for which numerous ESTs were available (Table
2; see Additional file 1). Remarkably, however, the list
included 30 moderately or even weakly expressed genes
that had no synonymous substitutions but had from 4 to
22 non-synonymous substitutions (Table 2; see Addi-
tional file 1).
Cancer connections of CASPS genes and biological 
implications
Objectively assessing the relevance of a particular gene to
tumorigenesis is no easy task. Numerous genes are linked
to one or another aspect of cell proliferation, and the
expression of many others is perturbed in tumors, which
does not necessarily point to an actual role in tumorigen-
esis. With all these caveats in mind, we nevertheless col-
lated the available data on biological properties of the
genes with an apparent signature of positive selection in
cancer-derived and normal ESTs and examined their
established and potential connections to tumorigenesis.
This examination indicated that 42 of the 112 CASPS
genes had definitive, experimentally supported connec-
tions to tumorigenesis (labeled 'yes' in Table 2; see Addi-
tional file 1 ), and for 21 more genes, indirect but strongly
suggestive evidence of cancer connections was available
(labeled 'likely'). The CASPS genes include those for sev-
eral proteins involved in DNA repair, programmed cell
death, and various forms of signal transduction, among
which ubiquitin signaling was particularly prominently
represented. All these proteins are directly linked to the
control of cell proliferation. Many other CASPS genes do
not have such well-defined roles but are substantially
overexpressed or amplified in certain types of tumors,
which is compatible with involvement in tumorigenesis
(Table 2; see Additional file 1).
Figures 1, 2, 3 show the distributions of putative somatic
mutations in the sequences of three CASPS genes. These
distributions illustrate the complexity of mutational pat-
terns, with distinct spectra seen in cancer and normal
ESTs, and a variety of cancer-specific and normal-specific
hotspots (Figs. 1,2). Note, however, the presence of a SNP
in the same position in both cancer and normal ESTs (Fig.
3)
The CASPS genes included only one well-characterized
oncogene, the ret protooncogene (Table 2; see Additional
file 1). We compared the list of CASPS genes to the com-
prehensive list of cancer-related set reported in a recent
census [13]. In our analysis of EST sequences, mutation
spectra with more than 5 mutations were detected for 83
of the 249 cancer-related genes, and 5 of these belonged
to the CASPS list. The probability of observing 5 or more
genes from a list of 249 among the 112 CASPS genes is
~0.025, suggesting a weak but non-random connection
between the CASPS genes detected here and previously
characterized cancer-related genes.
Discussion
The interpretation of the findings on CASPS genes
described here requires extreme caution. Although filters
were applied to separate somatic mutations from
sequencing errors and SNPs (see Methods for details), it is
impossible to guarantee that the final list is free of these
irrelevant sources of variation. Furthermore, taking into
consideration the number of analyzed ESTs, identification
of 112 genes with apparent signs of positive selection is,
in itself, not particularly surprising. The strongest indica-
tion we obtained that some of the CASPS genes are likely
to be associated with tumorigenesis is the significant
excess of genes with the positive selection signature
among cancer ESTs compared to the ESTs from normal tis-
sues (112 against 37). Based on this ratio and assuming
that the apparent signature of positive selection in normal
ESTs represents the background noise, it should be
expected that ~70% of the CASPS genes are, indeed, sub-
ject to positive selection during the somatic evolution of
tumors. Additionally, the evidence seems convincing for
those genes that, individually, showed a significant differ-
ence in the non-synonymous to synonymous substitution
ratio between cancer and normal ESTs (Table 2; see Addi-
tional file 1). From a different perspective, however, it is
not certain that somatic mutations in normal tissues are
not selected for. Furthermore, it cannot be ruled out that
some of the genes that seem to evolve under positive
selection in normal tissues are associated with the devel-
opment of precancerous conditions.
Assuming that there is, indeed, a signal of tumor-specific
positive selection in our list of CASPS genes, these are
likely to be the tip of the proverbial iceberg of genes that
evolve under this regimen in various cancers. Although
the current EST database is large and represents most of
human genes, it is far from being satisfactory for the pur-
pose of analysis of somatic evolution. In the present
study, we had no choice but to lump together ESTs from
all types of cancers because the amount of variation inBMC Cancer 2006, 6:36 http://www.biomedcentral.com/1471-2407/6/36
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individual tumor types was insufficient for statistical anal-
ysis. Furthermore, as already indicated, this analysis is
capable of detecting selection only for relatively highly
expressed genes. Many genes on our CASPS list and more
genes that did not make it contained only several non-
synonymous substitutions with no synonymous substitu-
tions. Obviously, the statistical power of the present anal-
ysis was insufficient to identify positive selection in these
genes.
It is expected that, once the EST or complete cDNA data
becomes sufficient for separate analysis of tumors of dif-
ferent origins or, ideally, different cell types and tumor
progression stages from individual patients, approaches
similar to those employed in this work will provide a
wealth of information on somatic evolution of the cancer
genome. Establishing ancestor-descendant relationships
within individuals will allow one to arrive to definitive
conclusions regarding the selection forces in action during
tumorigenesis.
Conclusion
With all due caution, those genes in the CASPS list that
met both criteria (significant excess of synonymous muta-
tions and significant difference between cancer and nor-
mal ESTs) could be interesting candidates for a detailed
analysis aimed at characterization of new oncogenes or
genes with other, still poorly understood roles in tumori-
genesis. Furthermore, the results of this work emphasize
the value of massive EST and mRNA sequencing from var-
ious tumor types (or, ideally, from individual tumors) for
identifying the complete catalog of genes with a causal
role in tumorigenesis.
Methods
Data and sequence comparisons
The 25801 non-redundant (all identical sequences were
removed) coding sequences (CDS) of human genes from
the human genome draft build 35, the April 2004 freeze,
obtained at the NCBI ftp server [37] were used as reference
sequences to be compared with the EST sequences. The
EST sequences were from the dbEST release of August,
2004 [38]. EST Library information was extracted and
loaded into a mysql database [39]. Each library was man-
ually curated and assigned to either cancer – related (1413
entries) or normal tissue (1370 entries) bins.
The CDS set was searched against dbEST using the
BLASTN program with the default parameters[40]. Uni-
gene Build #173 [41] was used to assign ESTs to a particu-
lar locus. Overall, 1844057 Unigene EST hits were
identified (Table 1).
The database of single-nucleotide polymorphisms
(dbSNP) in the fasta format was downloaded from [42] as
of May, 2004 (build 121). Altogether, 20573 non-redun-
dant SNPs were identified in the analyzed set of the CDS
to the dbSNP consortium specifications [43] by perform-
ing a MEGABLAST search of CDS set against dbSNP (com-
mand line: megablast -U T -F m -J F -X 180 -r 10 -q -20 -P
1000 -R T -W 28). All alignments containing gaps were
discarded. Using a custom PERL script, the MEGABLAST
report was parsed for reliable SNPs by ensuring the iden-
tity of the RefSeq sequence with the sequence in dbSNP.
Identification of probable somatic mutations in EST 
sequences
To ensure that all analyzed substitutions came from high-
quality sequence, a single-nucleotide substitution in an
EST sequence was considered a probable somatic muta-
tion if it was flanked, from each side, with 15 nucleotide
stretches of perfect identity between the EST sequence and
the reference sequence (CDS) and, in addition, a 50-
nucleotide stretch with at most 3 mismatches flanking the
identical 15 mers on each side. Substitutions that coin-
cided with SNPs from dbSNP and redundant substitu-
tions from the same EST library were discarded. The latter,
highly conservative filter was applied to eliminate possi-
ble additional, relatively rare SNPs, which are not
reported in the current release of dbSNP, and to ensure
clonality of all analyzed mutations. The effects of these fil-
ters on the analyzed mutations spectra are shown in Table
4. Statistical significance of differences between substitu-
tion spectra was determined using a modified χ2 test [36].
Table 4: The effects of filtering for SNPs and redundant substitutions on the substitution spectra
Raw data After removing SNPs After removing redundant mutations
# spectra (ESTs 
with substitutions)
# substitutions # spectra (ESTs 
with substitutions)
# substitutions # spectra (ESTs 
with substitutions)
# substitutions
Cancer 13961 388381 13961 311756 10305 253634
Normal 17116 736031 17116 527018 10352 410800BMC Cancer 2006, 6:36 http://www.biomedcentral.com/1471-2407/6/36
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Statistical significance of the differences between ratios of 
non-synonymous to synonymous substitutions
For each EST, the numbers of synonymous and non-syn-
onymous and substitutions was calculated. These num-
bers was compared to: i) expected numbers and ii) the
numbers for the respective genes in the ESTs from normal
(cancer) tissues. The expected values were calculated using
a Monte-Carlo random permutation procedure, which
was repeated 1000 times for each mutation spectrum.
Each step involved random shuffling of transitions/trans-
versions along the appropriate nucleotide sites in the
CDS, e.g., for a mutation A->G, the acceptable sites for
permutations were those that contained A. Binomial 1-
tailed test was used for assessing the statistical significance
of non-synonymous vs synonymous substitutions bias in
the form:
Where n = Nobs+Sobs is the total number of non-synony-
mous and synonymous substitutions observed,
 is the ratio of the number of non-synonymous
substitutions derived from the Monte-Carlo procedure to
the total number of substitutions, and q = 1-p.
One-tailed Fisher's exact test was used to assess the signif-
icance of the difference between the cancer and normal
substitution spectra.
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